BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 35414106)

  • 1. Stop of proton-pump inhibitor treatment in patients with liver cirrhosis (STOPPIT): study protocol for a prospective, multicentre, controlled, randomized, double-blind trial.
    Wehmeyer MH; Horvatits T; Buchholz A; Krause L; Walter S; Zapf A; Lohse AW; Kluwe J;
    Trials; 2022 Apr; 23(1):302. PubMed ID: 35414106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
    Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis.
    De Roza MA; Kai L; Kam JW; Chan YH; Kwek A; Ang TL; Hsiang JC
    World J Gastroenterol; 2019 Sep; 25(33):4933-4944. PubMed ID: 31543684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
    Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
    Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dexamethasone in patients with ARDS and COVID-19 - prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial.
    Maláska J; Stašek J; Duška F; Balík M; Máca J; Hruda J; Vymazal T; Klementová O; Zatloukal J; Gabrhelík T; Novotný P; Demlová R; Kubátová J; Vinklerová J; Svobodník A; Kratochvíl M; Klučka J; Gál R; Singer M;
    Trials; 2021 Mar; 22(1):172. PubMed ID: 33648568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.
    Barco S; Bingisser R; Colucci G; Frenk A; Gerber B; Held U; Mach F; Mazzolai L; Righini M; Rosemann T; Sebastian T; Spescha R; Stortecky S; Windecker S; Kucher N
    Trials; 2020 Sep; 21(1):770. PubMed ID: 32907635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of the long-term use of proton pump inhibitors by a patient-oriented electronic decision support tool (arriba-PPI): study protocol for a randomized controlled trial.
    Rieckert A; Becker A; Donner-Banzhof N; Viniol A; Bücker B; Wilm S; Sönnichsen A; Barzel A
    Trials; 2019 Nov; 20(1):636. PubMed ID: 31752978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.
    Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF
    Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of proton pump inhibitors in hospitalization on mortality of patients with hepatic encephalopathy and cirrhosis but no active gastrointestinal bleeding.
    Hung TH; Lee HF; Tseng CW; Tsai CC; Tsai CC
    Clin Res Hepatol Gastroenterol; 2018 Sep; 42(4):353-359. PubMed ID: 29551615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton pump inhibitor treatment is associated with acute-on-chronic liver failure in patients with advanced cirrhosis.
    Sturm L; Gahm C; Schultheiss M; Reincke M; Huber JP; Boettler T; Thimme R; Bettinger D
    Hepatol Commun; 2023 Jul; 7(7):. PubMed ID: 37347229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study.
    Tsai CF; Chen MH; Wang YP; Chu CJ; Huang YH; Lin HC; Hou MC; Lee FY; Su TP; Lu CL
    Gastroenterology; 2017 Jan; 152(1):134-141. PubMed ID: 27639806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.
    Targownik LE; Fisher DA; Saini SD
    Gastroenterology; 2022 Apr; 162(4):1334-1342. PubMed ID: 35183361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
    Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose vitamin D versus placebo to prevent complications in COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial (CARED-TRIAL).
    Mariani J; Tajer C; Antonietti L; Inserra F; Ferder L; Manucha W
    Trials; 2021 Feb; 22(1):111. PubMed ID: 33522946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deleterious effect of proton pump inhibitors on the disease course of cirrhosis.
    Janka T; Tornai T; Borbély B; Tornai D; Altorjay I; Papp M; Vitális Z
    Eur J Gastroenterol Hepatol; 2020 Feb; 32(2):257-264. PubMed ID: 31464790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with proton pump inhibitors in acute non-variceal upper gastrointestinal bleeding: a meta-analysis.
    Khuroo MS; Khuroo MS; Farahat KL; Kagevi IE
    J Gastroenterol Hepatol; 2005 Jan; 20(1):11-25. PubMed ID: 15610441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.